CVAC and FANS reflect different surgical philosophies—dusting vs fragmentation—with distinct ergonomic trade-offs and shared intrarenal pressure risks that urologists must actively monitor, according ...

FDA cleared Titan Prime, a next-generation IPP, emphasizing improved flaccid flexibility intended to enhance comfort and concealability for erectile dysfunction patients. Approval of generic Ga-68 ...

The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline. Two overarching themes define the 2026 amendment: the consolidation ...

Labeling would drop the limitation of use for age-related hypogonadism, reflecting an evidence reassessment that no longer supports language implying unestablished safety and effectiveness in this ...

Louise Emmett, MD, PhD, MBChB, FRACP, discusses findings from the phase 1 AcTION trial, which evaluated the safety and preliminary activity of 225Ac-PSMA-617 in patients with metastatic ...

Praful Ravi, MB, BChir, MRCP, discusses results from PSMAtrack, which assessed changes in PSMA-PET during initial systemic therapy for metastatic hormone-sensitive prostate cancer. According to Ravi, ...

DPMC was independently prognostic in mHSPC, with higher scores associating with worse OS and enrichment for adverse features (Gleason 8–10, synchronous metastases, younger age). Nonrandom docetaxel ...

The management of testicular cancer continues to evolve, with advances in diagnostics, risk stratification, and multimodal treatment shaping contemporary clinical practice. At the 41st Annual Congress ...

Pre-operative counseling should frame vasectomy as intended permanent contraception, individualized to reproductive goals, and can be delivered virtually or in person while directly addressing ...

A central theme is the widening gap between clinical work and health care policy. In this episode of The Expert APProach: Conversations in Uro-Oncology, the conversation expands beyond clinical care ...

VYBRIQUE is a sildenafil oral film formulated for discreet, water-free administration, aiming to reduce use barriers for patients for whom privacy and convenience influence ED treatment adherence. A ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...